

# Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment

**Running Title:** *Roden et al.; Drug Interactions on QTc in Exploratory COVID-19 Treatment*

Dan M. Roden, M.D.C.M.<sup>1</sup>; Robert A. Harrington, MD<sup>2</sup>; Athena Poppas, MD<sup>3</sup>; Andrea M. Russo, MD<sup>4</sup>

<sup>1</sup>Interim Division Chief, Division of Cardiovascular Medicine; Senior Vice President for Personalized Medicine; Clinical Cardiac Electrophysiology Program Faculty, Vanderbilt University School of Medicine, Nashville, TN; <sup>2</sup>Arthur L. Bloomfield Professor of Medicine; Chair, Department of Medicine, Stanford University, Stanford, CA; <sup>3</sup>Chief of the Cardiology Division, Professor of Medicine, Brown University School of Medicine, Providence, RI; <sup>4</sup>Director of Electrophysiology and Arrhythmia Services at Cooper University Hospital, Director of the CCEP Fellowship Program, Professor of Medicine at Cooper Medical School of Rowan University, Camden, NJ

Dr. Harrington is president of the American Heart Association. Dr. Poppas is president of the American College of Cardiology. Dr. Russo is president of the Heart Rhythm Society.

**Address for Correspondence:**

Dan M. Roden, M.D.C.M.  
Vanderbilt University School of Medicine  
1285B Medical Research Building-IV  
2215B Garland Avenue  
Nashville, TN 37232-0575  
Email: dan.rodan@vumc.org

Copyright 2020 by the American Heart Association, Inc., American College of Cardiology Foundation, and Heart Rhythm Society.

Hydroxychloroquine and azithromycin have been touted for potential prophylaxis or treatment for COVID-19 (coronavirus disease 2019) infection. Both drugs are listed as definite causes of torsade de pointes at [crediblemeds.org](http://crediblemeds.org). There are occasional case reports of hydroxychloroquine prolonging the QT interval and provoking torsade de pointes<sup>1-4</sup> when used to treat systemic lupus erythematosus. Antimalarial prophylactic drugs, such as hydroxychloroquine, are believed to act on the entry and post-entry stages of SARS-CoV (severe acute respiratory syndrome–associated coronavirus) and SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection, likely via effects on endosomal pH and the resulting under-glycosylation of angiotensin-converting enzyme 2 receptors that are required for viral entry.<sup>5</sup>

The widely used antibiotic azithromycin is increasingly recognized as a rare cause of QT prolongation,<sup>6,7</sup> serious arrhythmias,<sup>8,9</sup> and increased risk for sudden death<sup>10</sup>; advanced age and female sex have been implicated as risk factors. Interestingly, azithromycin can also provoke non-pause–dependent polymorphic ventricular tachycardia.<sup>11,12</sup> The FDA *Perspective* supported the observations that azithromycin administration leaves the patient vulnerable to QTc interval prolongation and torsade de pointes.<sup>13</sup>

Basic electrophysiologic studies suggest that both drugs can provoke proarrhythmia via mechanisms beyond block of  $I_{Kr}$  implicated in usual cases of torsade de pointes.<sup>14,15</sup> The effect of the combination of these agents on QT or arrhythmia risk has not been studied. There are very limited data evaluating the safety of combination therapy. Multiple randomized trials are currently being initiated.

Seriously ill patients often have comorbidities that can increase risk of serious arrhythmias. These include hypokalemia, hypomagnesemia, fever,<sup>16</sup> and an inflammatory state.<sup>17</sup> Mechanisms to minimize arrhythmia risk include:

- Electrocardiographic/QT interval monitoring:
  - Withhold the drugs in patients with baseline QT prolongation (eg, QTc  $\geq$ 500 msec) or with known congenital long QT syndrome.
  - Monitor cardiac rhythm and QT interval; withdrawal of the drugs if QTc exceeds a preset threshold of 500 msec.
  - In patients critically ill with COVID-19 infection, frequent caregiver contact may need to be minimized, so optimal electrocardiographic interval and rhythm monitoring may not be possible.
- Correction of hypokalemia to levels of  $>4$  mEq/L and hypomagnesemia to levels of  $>2$  mg/dL.
- Avoid other QTc prolonging agents<sup>5</sup> whenever feasible.



Safety considerations for use of hydroxychloroquine and azithromycin in clinical practice have been described.<sup>18</sup>

Some of the current COVID-19 repurposed drugs are listed in the Table.

### Sources of Funding

None

### Disclosures

Dr. Roden has nothing to disclose. Dr. Harrington serves on the AHA Board of Directors (unpaid); he also served on the Stanford Healthcare Board of Directors from 2016-2018 (unpaid). Dr. Poppas has nothing to disclose. Dr. Russo receives research study support from the following (all funding to the hospital): Boehringer Ingelheim, Boston Scientific, and Medilynx. She also

serves on the Research Steering Committee (no honoraria) for Boston Scientific and the Apple Heart Study.

### References

1. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. *Clin Toxicol (Phila)*. 2006;44:173-175.
2. Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. *J Clin Rheumatol*. 2013;19:286-288.
3. O'Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. *Case Reports in Cardiology*. 2016;2016:4626279. doi: 10.1155/2016/4626279.
4. de Olano J, Howland MA, Su MK, Hoffman RS, Biary R. Toxicokinetics of hydroxychloroquine following a massive overdose. *Am J Emerg Med*. 2019;37:2264.e5-2264.e8.
5. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19 [published online ahead of print March 25, 2020]. *Mayo Clin Proc*. doi: 10.1016/j.mayocp.2020.03.024. [https://www.elsevier.com/\\_data/assets/pdf\\_file/0004/996745/MCP\\_Possible-COVID-19-Pharmacotherapies.pdf](https://www.elsevier.com/_data/assets/pdf_file/0004/996745/MCP_Possible-COVID-19-Pharmacotherapies.pdf). Accessed April 2, 2020.
6. Choi Y, Lim H-S, Chung D, Choi J-G, Yoon D. Risk evaluation of azithromycin-induced QT prolongation in real-world practice. *BioMed Research International*. 2018:1574806. doi: 10.1155/2018/1574806.
7. Sears SP, Getz TW, Austin CO, Palmer WC, Boyd EA, Stancampiano FF. Incidence of sustained ventricular tachycardia in patients with prolonged QTc after the administration of azithromycin: a retrospective study. *Drugs Real World Outcomes*. 2016;3:99-105.
8. Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. *Pacing Clin Electrophysiol*. 2007;30:1579-1582.
9. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. *J Interv Card Electrophysiol*. 2007;18:243-246.
10. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. *N Engl J Med*. 2012;366:1881-1890.
11. Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. *Pacing Clin Electrophysiol*. 2005;28:1221-1222.
12. Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, Luis PB, Hall L, Zhang W, Du L, et al. Azithromycin causes a novel proarrhythmic syndrome. *Circ Arrhythm Electrophysiol*. 2017;10:e003560.
13. Mosholder AD, Mathew J, Alexander JJ, Smith H., Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. *N Engl J Med*. 2013;368:1665-1668.

14. Zhang M, Xie M, Li S, Gao Y, Xue S, Huang H, Chen K, Liu F, Chen L. Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin. *Cardiovasc Toxicol*. 2017;17:434-440.
15. Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, Bub G, Channon K, Paterson DJ, Terrar DA, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current  $I_f$ : novel electrophysiological insights and therapeutic potential. *Heart Rhythm*. 2015;12:2186-2194.
16. Kauthale RR, Dadarkar SS, Husain R, Karande VV, Gatne MM. Assessment of temperature-induced hERG channel blockade variation by drugs. *J Appl Toxicol*. 2015;35:799-805.
17. Aromolaran AS, Srivastava U, Ali A, Chahine M, Lazaro D, El-Sherif N, Capecchi PL, Laghi-Pasini F, Lazzarini PE, Boutjdir M. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. *PloS One*. 2018;13:e0208321.
18. Simpson TF, Kovacs RJ, Stecker EC. Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. Published online March 29, 2020. <https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19>. Accessed April 2, 2020.



# Circulation

**Table.** Torsade de pointes potential and post-marketing adverse events associated with possible COVID-19 repurposed pharmacotherapies.

Possible COVID-19 Treatment	CredibleMeds Classification	VT/VF/TdP/LQTS in FAERS	Cardiac Arrest in FAERS
<b>Repurposed antimalarial agents</b>			
Chloroquine	Known risk	72	54
Hydroxychloroquine	Known risk	222	105
<b>Repurposed antiviral agents</b>			
Lopinavir/ritonavir	Possible risk	27	48
<b>Adjunct agents</b>			
Azithromycin	Known risk	396	251

COVID-19 indicates coronavirus disease 2019; FAERS, US Food and Drug Administration Adverse Event Reporting System; LQTS, long QT syndrome; and TdP, torsade de pointes.

Used with permission from Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19 [published online ahead of print March 25, 2020]. *Mayo Clin Proc*. doi: 10.1016/j.mayocp.2020.03.024.

[https://www.elsevier.com/\\_\\_data/assets/pdf\\_file/0004/996745/MCP\\_Possible-COVID-19-Pharmacotherapies.pdf](https://www.elsevier.com/__data/assets/pdf_file/0004/996745/MCP_Possible-COVID-19-Pharmacotherapies.pdf). Accessed April 2, 2020.<sup>5</sup>



Circulation